| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.advikindia.com | |
| Market Cap | 3.82 Cr. | |
| Enterprise Value(EV) | 10.21 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.17 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 32.90 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | 1.75 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | 1.14 | Calculated using Price: 2.00 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.91 Cr. | 19,111,400 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| Advik Laboratories has been set up by V K Jain, a qualified production chemist with over 20 years experience in pharmaceutical products. | ||
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
+4.71% |
| 3 Month |
|
+9.89% |
| 6 Month |
|
+20.48% |
| 1 Year |
|
+50.38% |
| 2 Year |
|
+455.56% |
| 5 Year |
|
-70.24% |
| 10 Year |
|
-69.37% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 3.24 | -4.03 | -6.79 | -48.30 | -7.74 | -12.28 | -13.04 | -71.73 | -3.64 | |
| Return on Capital Employed (%) | 8.13 | 0.59 | -4.23 | -33.90 | -5.91 | -7.76 | -8.08 | -36.90 | -9.64 | |
| Return on Assets (%) | 1.45 | -2.01 | -3.91 | -29.85 | -4.32 | -6.79 | -6.87 | -31.87 | -1.32 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 20 | 19 | 19 | 12 | 11 | 10 | 8 | 4 | 4 | 3 | |
| Non Curr. Liab. | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | |
| Curr. Liab. | 10 | 10 | 7 | 8 | 8 | 7 | 7 | 7 | 6 | 7 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 35 | 32 | 29 | 21 | 19 | 18 | 16 | 11 | 10 | 10 | |
| Non Curr. Assets | 16 | 15 | 15 | 14 | 13 | 12 | 11 | 9 | 8 | 8 | |
| Curr. Assets | 19 | 17 | 14 | 7 | 7 | 5 | 5 | 2 | 2 | 2 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 35 | 32 | 29 | 21 | 19 | 18 | 16 | 11 | 10 | 10 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 30 | 12 | 1 | 3 | 4 | 1 | 0 | 0 | |||
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Total Income | 30 | 12 | 1 | 3 | 4 | 1 | 0 | 0 | 0 | 0 | |
| Total Expenditure | -27 | -11 | -2 | -10 | -5 | -2 | -1 | -4 | -1 | -1 | |
| PBIDT | 3 | 1 | 0 | -7 | 0 | -1 | -1 | -4 | 0 | -1 | |
| Interest | -1 | -1 | 0 | ||||||||
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | 0 | |
| Taxation | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Exceptional Items | |||||||||||
| PAT | 0 | -1 | -1 | -7 | -1 | -1 | -1 | -4 | 0 | 0 | |
| Adjusted EPS | 0 | 0 | -1 | -4 | 0 | -1 | -1 | -2 | 0 | 0 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 5 | 2 | 1 | 0 | 0 | 1 | 0 | -1 | -4 | |
| Cash Fr. Inv. | 0 | -6 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | |
| Cash Fr. Finan. | 0 | 2 | -2 | -1 | -1 | 0 | 0 | -1 | 4 | ||
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Mon, 23 Jan 2023
Board Meeting Intimation for Notice Of Board Meeting To Consider The Un-AuditedFinancial Results Of The Company For The Quarter Ended 31 St December 2022 ADVIK LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (LODR) Regulations 2015 notice is hereby given that as per the requirements of Regulation 33 of the Securities and Exchange Board of India (LODR) Regulations 2015 a meeting of the Board of Directors of the company is scheduled to be held on Friday 03rd February 2023 at 12:00 P.M at the corporate office of the company at 703 Arunachal Building 19 Barakhambha Road Connaught Place New Delhi-110001 to inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended 31st December 2022 and to carry on any other business with the permission of the Board. |
|
Sat, 21 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 With reference to the subject matter captioned above we are enclosing herewith the Certificateunder Regulation 74(5) of SEBI (Depository and Participant) Regulations 2018 for the quarterended 31st December 2022 received from M/s. MAS Services Private Limited the Registrar andShare Transfer Agent of our Company. |
|
Thu, 12 Jan 2023
Statement Of Investor Complaints For The Quarter Ended 31St December 2022 As per the requirements of Regulation 13(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 please find herein attached the Statement of Investor Complaints for the quarter ended 31st December 2022 for your kind perusal. |
|
No Scans Found |
Equities
M.F.
Sectors